Dr. Sara Tolaney On Adjuvant Cisplatin And Radiation For Triple-Negative Breast Cancer

Dr. Sara Tolaney on Adjuvant Cisplatin and Radiation for Triple-Negative Breast Cancer

Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer

Touch Medical Media

Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer

Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast Cancer

Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC

Dr. Tolaney on Platinum-Based Therapy in Neoadjuvant Setting of TNBC

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer

Triple Negative Breast Cancer - with Dr. Tasha

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

Dr. Tolaney on the Evolution of Adjuvant Treatment for HER2+ Breast Cancer

Dr. Cynthia Ma on Immunotherapy in TNBC

Dana-Farber Cancer Institute | Sara Tolaney, MD, MPH, at SABCS 2020

Dana-Farber Cancer Institute

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBC

Targeted Oncology

Dr. Formenti on Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy in TNBC

ESMO22: Breast cancer research by Sara Tolaney, MD (TROPiCS) | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Sara Tolaney on Eribulin Plus Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Can...

Research To Practice

Dr Sara M. Tolaney: Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer

Treatment optimization trials in breast cancer